Pharvaris NV (NASDAQ: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema, on Tuesday announced positive top-line results from its CHAPTER-3 pivotal Phase 3 study of deucrictibant extended-release (XR) for preventing hereditary angioedema (HAE) attacks.
The company plans to use the data to support marketing authorisation applications from the first half of 2027.
The global, double-blind, placebo-controlled study enrolled 85 participants across 21 countries and evaluated once-daily deucrictibant XR for 24 weeks. Participants receiving deucrictibant XR recorded an 83% reduction in mean monthly attack rate versus placebo (p
Innovent Biologics achieves primary study endpoint for inactive thyroid eye disease antibody
argenx reports positive Phase 2 results for FB102 in coeliac disease
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
Suzhou Ribo Life Science submits Phase I Clinical Trial Application for RBD3133 in EU
Roche Diagnostics supplies molecular testing instruments to support Ebola response in the DRC